Basiliximab and infliximab for the treatment of steroid-refractory Crohn's disease.
Michelle
M
Price
Christopher S J
CS
Probert
Tom
T
Creed
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000077552:Basiliximab; D003424:Crohn Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005765:Gastrointestinal Agents / Q000008:administration & dosage; D005938:Glucocorticoids / Q000494:pharmacology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D000069285:Infliximab; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D000069285:Infliximab